Aigen Investment Management LP Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Key Points

• Aigen Investment Management LP has acquired 9,522 shares of TG Therapeutics, Inc. (NASDAQ:TGTX), valued at approximately $375,000, during the first quarter.
• Director Yann Echelard sold 10,000 shares at an average price of $36.94, reducing his ownership by 4.19%, while retaining 228,816 shares valued at around $8.45 million.
• TG Therapeutics reported a 92.1% increase in revenue year-over-year, with an EPS of $0.17 for the latest quarter, falling short of analysts’ expectations by $0.15.

Aigen Investment Management LP bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 9,522 shares of the biopharmaceutical company's stock, valued at approximately $375,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC grew its position in shares of TG Therapeutics by 16.2% in the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after buying an additional 290 shares during the last quarter. Golden State Wealth Management LLC grew its position in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares during the last quarter. Xponance Inc. grew its position in shares of TG Therapeutics by 5.3% in the 1st quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock valued at $428,000 after buying an additional 543 shares during the last quarter. Finally, Choreo LLC boosted its position in shares of TG Therapeutics by 7.6% during the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock valued at $337,000 after purchasing an additional 602 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Activity at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.64% of the company's stock.

TG Therapeutics Trading Up 1.1%

Shares of TG Therapeutics stock traded up $0.31 on Friday, hitting $28.08. 1,811,717 shares of the company's stock traded hands, compared to its average volume of 2,818,288. TG Therapeutics, Inc. has a one year low of $20.81 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 3.04. The company has a fifty day moving average of $35.07 and a two-hundred day moving average of $35.83. The company has a market capitalization of $4.46 billion, a price-to-earnings ratio of 75.89 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%. The firm's quarterly revenue was up 92.1% compared to the same quarter last year. During the same period last year, the company posted $0.04 earnings per share. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $46.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.